Table 3 Mean scores before the first course of chemotherapy, changes of scores between the first and the fourth courses of responsiveness statistics in patients who perceived improved health (n = 17)
n | Score before 1stchemother.Mean (SD a) | Difference Mean (SD a) | Pb | SRMc (CI 95%) | ESd (CI 95%) | |
|---|---|---|---|---|---|---|
EORTC QLQ-C30: | ||||||
Functional scalese : | ||||||
Physical function | 16 | 67.8 (30.2) | +14.9 (22.5) | 0.02 | 0.64 (0.19;1.08) | 0.48 (0.14;0.86) |
Role function | 16 | 55.9 (39.1) | +21.9 (16.7) | 0.03 | 0.60 (0.08;1.13) | 0.56 (0.10;1.07) |
Emotional function | 17 | 69.6 (16.1) | +16.2 (16.7) | 0.003 | 0.84 (0.28;1.54) | 1.00 (0.35;1.68) |
Cognitive function | 17 | 77.5 (20.4) | +10.8 (16.6) | 0.02 | 0.64 (0.16;1.29) | 0.52 (0.14;1.09) |
Social function | 17 | 62.7 (34.1) | +13.7 (38.3) | 0.16 | 0.35 (-0.17;0.88) | 0.40 (-0.20;0.89) |
Global QoL/GHS | 17 | 54.9 (20) | +14.2 (14.7) | 0.001 | 0.96 (0.38;1.67) | 0.71 (-0.23;1.44) |
Symptom scalesf : | ||||||
Fatigue | 16 | 42.8 (27.9) | -16.3 (25.8) | 0.02 | - 0.63 (-1.07;-0.19) | - 0.58 (-1.13;-0.15) |
Pain | 17 | 28.4 (31) | -17.6 (37.5) | 0.07 | - 0.47 (-0.90;-0.09) | - 0.56 (-1.07;-0.05) |
Nausea and vomiting | 16 | 12.7 (22.5) | -6.2 (21.8) | 0.27 | - 0.28 (-0.69;0.28) | - 0.27 (-0.66;0.25) |
Single itemsf : | ||||||
Dyspnoea | 16 | 21.6 (26.2) | -8.3 (25.8) | 0.22 | - 0.32 (-1.05;0.65) | - 0.31 (-0.89;0.17) |
Sleep disturbance | 16 | 45.1 (31) | -12.5 (38.2) | 0.21 | - 0.32 (-0.86;0.19) | - 0.40 (-0.98;0.38) |
Appetite loss | 16 | 29.4 (30.9) | -12.5 (26.9) | 0.08 | - 0.46 (-0.93;0.01) | - 0.40 (-0.87;0.08) |
Diarrhoea | 17 | 19.6 (23.7) | +3.9 (33.1) | 0.63 | 0.11 (-0.38;0.64) | 0.16 (-0.41;1.17) |
Constipation | 17 | 17.6 (29.1) | -5.9 (27.0) | 0.38 | - 0.21 (-0.75;0.31) | - 0.20 (-0.67;0.31) |
Financial impact | 17 | 5.9 (17.6) | +3.9 (11.1) | 0.16 | 0.35 (0.11;0.57) | 0.22 (-0.05;0.49) |
EORTC QLQ-CR38: | ||||||
Functional scalese: | ||||||
Body image | 16 | 81.7 (28) | +3.8 (14.2) | 0.30 | 0.27 (-0.33;0.69) | 0.13 (-0.13;0.37) |
Future perspective | 16 | 45.1 (28.7) | +22.9 (31.5) | 0.01 | 0.70 (0.27;1.27) | 0.79 (0.27;1.38) |
Sexual functioning | 14 | 20.2 (20.9) | +5.9 (16.8) | 0.21 | 0.37 (-0.28;0.86) | 0.28 (-0.15;0.83) |
Sexual enjoyment | 7 | 54.2 (43.4) | +9.5 (41.8) | 0.57 | 0.23 (-0.56;1.28) | 0.21 (-0.73;0.91) |
Symptom scalesf : | ||||||
Radiation-induced effects micturition | 16 | 23.5 (15.2) | +4.8 (15.7) | 0.23 | 0.30 (-0.23;0.91) | 0.32 (-0.23;0.89) |
Chemotherapy side effects | 16 | 18.6 (19.5) | +4.2 (18.4) | 0.38 | 0.23 (-0.30;1.1) | 0.21 (-0.77;0.92) |
General Gastrointestinal symptoms | 16 | 23.0 (12) | -7.0 (14.3) | 0.07 | -0.49 (-1.38;0.11) | - 0.58 (-1.45;0.17) |
Defecation problems | 13 | 15.4 (11.5) | -1.8 (8.2) | 0.43 | -0.22 (-1.10;0.41) | - 0.16 (-0.65;0.32) |
Stoma-related problems | 4 | 31.0 (21.5) | -1.2 (13.7) | 0.87 | -0.10 (-1.15;1.02) | - 0.05 (-1.96;2.43) |
Sexual dysfunction of men | 8 | 43.8 (41.7) | -2.1 (35.0) | 0.87 | -0.06 (-1.43;0.82) | - 0.04 (0.84;0.64) |
Sexual dysfunction of women | 2 | 8.3 (11.8) | -8.3 (11.8) | 0.50 | -0.70 (-1.44;-0.31) | -0.70 (-1.44;-0.31) |
Weight loss | 16 | 25.5 (34.4) | -22.9 (33.8) | 0.02 | -0.67 (-1.01;-0.35) | - 0.66 (-1.01;-0.36) |
FACT-Ce: | ||||||
Physical Well-Being | 17 | 78.0 (15.3) | +5.3 (15.8) | 0.18 | 0.34 (-0.20;0.85) | 0.34 (-0.17;0.87) |
Social/Family Well-Being | 17 | 74.3 (21.1) | +3.2 (18.3) | 0.48 | 0.17 (0.47;0.59) | 0.15 (-0.39;0.48) |
Emotional Well-Being | 17 | 74.3 (19.6) | +3.3 (13.7) | 0.34 | 0.24 (-0.32;0.64) | 0.16 (-0.16;0.48) |
Functional Well-Being | 17 | 50.8 (17.1) | +10.0 (13.2) | 0.007 | 0.75 (0.20;1.27) | 0.58 (0.19;0.93) |
Colorectal Cancer Specific | 16 | 69.6 (10.6) | +3.9 (12.9) | 0.25 | 0.30 (-0.26;0.88) | 0.36 (-0.27;0.98) |
FACT-C total score | 17 | 69.5 (8.6) | +1.6 (9.0) | 0.49 | 0.19 (-0.36;0.71) | 0.18 (-0.35;0.81) |
Trial Outcome Index-Colorectal | 17 | 66.4 (10.6) | +4.7 (13.0) | 0.152 | 0.36 (-0.20;0.96) | 0.44 (-0.29;0.99) |